Negative regulatory receptors of the IL-1 family

Seminars in Immunology

Volumn 25, Issue 6, 2013, Pages 408-415

  Garlanda, Cecilia ^a   Riva, Federica ^b   Bonavita, Eduardo ^a   Mantovani, Alberto ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Decoy receptor; Inflammation; Interleukin 1

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 DECOY RECEPTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ACPB; INTERLEUKIN 1 RECEPTOR APL; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 18 BINDING PROTEIN; TIGIRR 1 RECEPTOR; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG;

CYTOKINE PRODUCTION; CYTOKINE RESPONSE; GENE; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; MOLECULAR EVOLUTION; NEGATIVE REGULATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; REGULATORY MECHANISM; REVIEW; SIGIRR GENE;

DECOY RECEPTOR; INFLAMMATION; INTERLEUKIN-1;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-1; MACROPHAGES; MICE; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE II;

EID: 84892836003     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2013.10.019     Document Type: Review

References (130)

1. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science 2003, 300:1524-1525.
2. Towne J.E., Garka K.E., Renshaw B.R., Virca G.D., Sims J.E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 2004, 279:13677-13688.
3. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008, 223:20-38.
4. Dinarello C., Arend W., Sims J., Smith D., Blumberg H., O'Neill L., et al. IL-1 family nomenclature. Nat Immunol 2010, 11:973.
5. Born T.L., Smith D.E., Garka K.E., Renshaw B.R., Bertles J.S., Sims J.E. Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family. Delineation of a new class of IL-1R-related proteins based on signaling. J Biol Chem 2000, 275:29946-29954.
6. Hasan U., Chaffois C., Gaillard C., Saulnier V., Merck E., Tancredi S., et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005, 174:2942-2950.
7. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008, 226:10-18.
8. Dinarello C.A., Simon A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652.
9. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
10. van de Veerdonk F.L., Netea M.G. New insights in the immunobiology of IL-1 family members. Front Immunol 2013, 4:167.
11. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A., Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110:191-202.
12. Janssens S., Burns K., Vercammen E., Tschopp J., Beyaert R. MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression. FEBS Lett 2003, 548:103-107.
13. O'Neill L.A., Sheedy F.J., McCoy C.E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011, 11:163-175.
14. Colotta F., Re F., Muzio M., Bertini R., Polentarutti N., Sironi M., et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science 1993, 261:472-475.
15. McMahan C.J., Slack J.L., Mosley B., Cosman D., Lupton S.D., Brunton L.L., et al. A novel IL-1 receptor,cloned from B. cells by mammalian expression is expressed in many cell types. EMBO J 1991, 10:2821-2832.
16. Copeland N.G., Silan C.M., Kingsley D.M., Jenkins N.A., Cannizzaro L.A., Croce C.M., et al. Chromosomal location of murine and human IL-1 receptor genes. Genomics 1991, 9:44-50.
17. Morrison R.N., Young N.D., Nowak B.F. Description of an Atlantic salmon (Salmo salar L.) type II interleukin-1 receptor cDNA and analysis of interleukin-1 receptor expression in amoebic gill disease-affected fish. Fish Shellfish Immunol 2012, 32:1185-1190.
18. Novick D., Kim S.H., Fantuzzi G., Reznikov L.L., Dinarello C.A., Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10:127-136.
19. Watanabe M., Goto N., Watanabe Y., Nishiguchi S., Shimada K., Yasunga T., et al. Evolution of interleukin-18 binding proteins and interleukin-1 receptor, type II proteins. Int J Mol Med 2005, 15:561-566.
20. Wang D., Zhang S., Li L., Liu X., Mei K., Wang X. Structural insights into the assembly and activation of IL-1beta with its receptors. Nat Immunol 2010, 11:905-911.
21. Orlando S., Sironi M., Bianchi G., Drummond A.H., Boraschi D., Yabes D., et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem 1997, 272:31764-31769.
22. Lorenzen I., Lokau J., Dusterhoft S., Trad A., Garbers C., Scheller J., et al. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett 2012, 586:1093-1100.
23. Kuhn P.H., Marjaux E., Imhof A., De Strooper B., Haass C., Lichtenthaler S.F. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem 2007, 282:11982-11995.
24. Cui X., Rouhani F.N., Hawari F., Levine S.J. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 2003, 171:6814-6819.
25. Liu C., Hart R.P., Liu X.J., Clevenger W., Maki R.A., De Souza E.B. Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem 1996, 271:20965-20972.
26. Re F., Sironi M., Muzio M., Matteucci C., Introna M., Orlando S., et al. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function. J Exp Med 1996, 183:1841-1850.
27. Symons J.A., Young P.R., Duff G.W. Soluble type II interleukin 1 (IL-1) receptor binds blocks processing of IL-1 beta precursor loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 1995, 92:1714-1718.
28. Lang D., Knop J., Wesche H., Raffetseder U., Kurrle R., Boraschi D., et al. The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 1998, 161:6871-6877.
29. Malinowsky D., Lundkvist J., Laye S., Bartfai T. Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 1998, 429:299-302.
30. Laye S., Lundkvist J., Bartfai T. Human/mouse interleukin-1 receptor/receptor accessory protein interactions in IL-1beta-induced NFkappaB activation. FEBS Lett 1998, 429:307-311.
31. Jensen L.E., Muzio M., Mantovani A., Whitehead A.S. IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol 2000, 164:5277-5286.
32. Smith D.E., Hanna R., Della F., Moore H., Chen H., Farese A.M., et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003, 18:87-96.
33. Kawaguchi Y., Nishimagi E., Tochimoto A., Kawamoto M., Katsumata Y., Soejima M., et al. Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Proc Natl Acad Sci USA 2006, 103:14501-14506.
34. Zheng Y., Humphry M., Maguire J.J., Bennett M.R., Clarke M.C. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1alpha, controlling necrosis-induced sterile inflammation. Immunity 2013, 38:285-295.
35. Rauschmayr T., Groves R.W., Kupper T.S. Keratinocyte expression of the type 2 interleukin 1 receptor mediates local specific inhibition of interleukin 1-mediated inflammation. Proc Nat Acad Sci USA 1997, 94:5814-5819.
36. Bessis N., Guery L., Mantovani A., Vecchi A., Sims J.E., Fradelizi D., et al. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis. Eur J Immunol 2000, 30:867-875.
37. Khoufache K., Bondza P.K., Harir N., Daris M., Leboeuf M., Mailloux J., et al. Soluble human IL-1 receptor type 2 inhibits ectopic endometrial tissue implantation and growth: identification of a novel potential target for endometriosis treatment. Am J Pathol 2012, 181:1197-1205.
38. Dawson J., Engelhardt P., Kastelic T., Cheneval D., MacKenzie A., Ramage P. Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment. Rheumatology (Oxford) 1999, 38:401-406.
39. Simeoni E., Dudler J., Fleury S., Li J., Pagnotta M., Pascual M., et al. Gene transfer of a soluble IL-1 type 2 receptor-Ig fusion protein improves cardiac allograft survival in rats. Eur J Cardiothorac Surg 2007, 31:222-228.
40. Attur M.G., Dave M., Cipolletta C., Kang P., Goldring M.B., Patel I.R., et al. Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor. Potential for pharmacological intervention. J Biol Chem 2000, 275:40307-40315.
41. Chang H., Wang Y., Wu W., Li G., Hanawa H., Zou J. Hydrodynamics-based delivery of an interleukin-1 receptor II fusion gene ameliorates rat autoimmune myocarditis by inhibiting IL-1 and Th17 cell polarization. Int J Mol Med 2013, 31:833-840.
42. Alcami A., Koszinowski U.H. Viral mechanisms of immune evasion. Immunol Today 2000, 21:447-455.
43. Colotta F., Saccani S., Giri J.G., Dower S.K., Sims J.E., Introna M., et al. Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes. J Immunol 1996, 156:2534-2541.
44. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
45. Spriggs M.K., Nevens P.J., Grabstein K., Dower S.K., Cosman D., Armitage R.J., et al. Molecular characterization of the interleukin-1 receptor (IL-1R) on monocytes and polymorphonuclear cells. Cytokine 1992, 4:90-95.
46. Re F., Muzio M., De Rossi M., Polentarutti N., Giri J.G., Mantovani A., et al. The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 1994, 179:739-743.
47. Colotta F., Re F., Muzio M., Polentarutti N., Minty A., Caput D., et al. Interleukin-13 induces expression and release of interleukin-1 decoy receptor in human polymorphonuclear cells. J Biol Chem 1994, 269:12403-12406.
48. Dickensheets H.L., Donnelly R.P. IFN-gamma and IL-10 inhibit induction of IL-1 receptor type I and type II gene expression by IL-4 and IL-13 in human monocytes. J Immunol 1997, 159:6226-6233.
49. Kalliolias G.D., Gordon R.A., Ivashkiv L.B. Suppression of TNF-alpha and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J Immunol 2010, 185:7047-7056.
50. Daun J.M., Ball R.W., Burger H.R., Cannon J.G. Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo. J Leukoc Biol 1999, 65:863-866.
51. Penton-Rol G., Orlando S., Polentarutti N., Bernasconi S., Muzio M., Introna M., et al. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J Immunol 1999, 162:2931-2938.
52. Colotta F., Orlando S., Fadlon E.J., Sozzani S., Matteucci C., Mantovani A. Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells. J Exp Med 1995, 181:2181-2186.
53. Orlando S., Matteucci C., Fadlon E.J., Buurman W.A., Bardella M.T., Colotta F., et al. TNF-alpha, unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells. J Immunol 1997, 158:3861-3868.
54. Fettelschoss A., Kistowska M., LeibundGut-Landmann S., Beer H.D., Johansen P., Senti G., et al. Inflammasome activation IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Acad Sci USA 2011, 108:18055-18060.
55. Iwai H., Inaba M. Fetal thymus graft prevents age-related hearing loss and up regulation of the IL-1 receptor type II gene in CD4(+) T cells. J Neuroimmunol 2012, 250:1-8.
56. Drevets D.A., Schawang J.E., Mandava V.K., Dillon M.J., Leenen P.J. Severe Listeria monocytogenes infection induces development of monocytes with distinct phenotypic and functional features. J Immunol 2010, 185:2432-2441.
57. Martin P., Palmer G., Vigne S., Lamacchia C., Rodriguez E., Talabot-Ayer D., et al. Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions. J Leuk Biol 2013, 94:791-802.
58. Pou J., Martinez-Gonzalez J., Rebollo A., Rodriguez C., Rodriguez-Calvo R., Martin-Fuentes P., et al. interleukin-1 receptor expression is reduced in monocytes/macrophages and atherosclerotic lesions. Biochim Biophys Acta 2011, 1811:556-563.
59. Pinteaux E., Parker L.C., Rothwell N.J., Luheshi G.N. Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J Neurochem 2002, 83:754-763.
60. McNamee E.N., Ryan K.M., Kilroy D., Connor T.J. Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1beta-induced neurotoxicity. Eur J Pharmacol 2010, 626:219-228.
61. Docagne F., Campbell S.J., Bristow A.F., Poole S., Vigues S., Guaza C., et al. Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur J Neurosci 2005, 21:1205-1214.
62. Trebec D.P., Chandra D., Gramoun A., Li K., Heersche J.N., Manolson M.F. Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases. J Cell Biochem 2007, 101:205-220.
63. Vambutas A., DeVoti J., Goldofsky E., Gordon M., Lesser M., Bonagura V. Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS ONE 2009, 4:e5293.
64. Tran D.Q., Andersson J., Hardwick D., Bebris L., Illei G.G., Shevach E.M. Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures. Blood 2009, 113:5125-5133.
65. Mercer F., Kozhaya L., Unutmaz D. Expression and function of TNF and IL-1 receptors on human regulatory T cells. PLoS ONE 2010, 5:e8639.
66. Debets R., Hegmans J.P., Croughs P., Troost R.J., Prins J.B., Benner R., et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997, 158:2955-2963.
67. Akoum A., Jolicoeur C., Kharfi A., Aube M. Decreased expression of the decoy interleukin-1 receptor type II in human endometriosis. Am J Pathol 2001, 158:481-489.
68. Herrmann-Lavoie C., Rao C.V., Akoum A. Chorionic gonadotropin down-regulates the expression of the decoy inhibitory interleukin 1 receptor type II in human endometrial epithelial cells. Endocrinology 2007, 148:5377-5384.
69. Keita M., AinMelk Y., Pelmus M., Bessette P., Aris A. Endometrioid ovarian cancer and endometriotic cells exhibit the same alteration in the expression of interleukin-1 receptor II: to a link between endometriosis and endometrioid ovarian cancer. J Obstet Gynaecol Res 2011, 37:99-107.
70. Chun S., Kim H., Ku S.Y., Suh C.S., Kim S.H., Kim J.G. The association between endometriosis and polymorphisms in the interleukin-1 family genes in Korean women. Am J Reprod Immunol 2012, 68:154-163.
71. Akoum A., Al-Akoum M., Lemay A., Maheux R., Leboeuf M. Imbalance in the peritoneal levels of interleukin 1 and its decoy inhibitory receptor type II in endometriosis women with infertility and pelvic pain. Fertil Steril 2008, 89:1618-1624.
72. Grundtman C., Salomonsson S., Dorph C., Bruton J., Andersson U., Lundberg I.E. Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007, 56:674-687.
73. Ruckert F., Dawelbait G., Winter C., Hartmann A., Denz A., Ammerpohl O., et al. Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS ONE 2010, 5:e12243.
74. Ricote M., Garcia-Tunon I., Bethencourt F.R., Fraile B., Paniagua R., Royuela M. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer 2004, 100:1388-1396.
75. Laios A., O'Toole S.A., Flavin R., Martin C., Ring M., Gleeson N., et al. An integrative model for recurrence in ovarian cancer. Mol Cancer 2008, 7:8.
76. Chan K.Y., Leung F.W., Lam H.S., Tam Y.H., To K.F., Cheung H.M., et al. Immunoregulatory protein profiles of necrotizing enterocolitis versus spontaneous intestinal perforation in preterm infants. PLoS ONE 2012, 7:e36977.
77. Muller B., Peri G., Doni A., Perruchoud A.P., Landmann R., Pasqualini F., et al. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002, 72:643-649.
78. Dujmovic I., Mangano K., Pekmezovic T., Quattrocchi C., Mesaros S., Stojsavljevic N., et al. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol 2009, 207:101-106.
79. Arend W.P., Malyak M., Smith M.F., Whisenand T.D., Slack J.L., Sims J.E., et al. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol 1994, 153:4766-4774.
80. Jouvenne P., Vannier E., Dinarello C.A., Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. Arthritis Rheum 1998, 41:1083-1089.
81. Garlind A., Brauner A., Hojeberg B., Basun H., Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res 1999, 826:112-116.
82. Thomassen E., Renshaw B.R., Sims J.E. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 1999, 11:389-399.
83. Lech M., Garlanda C., Mantovani A., Kirschning C.J., Schlondorff D., Anders H.J. Different roles of TiR8/Sigirr on toll-like receptor signaling in intrarenal antigen-presenting cells and tubular epithelial cells. Kidney Int 2007, 72:182-192.
84. Riva F., Polentarutti N., Tribbioli G., Mantovani A., Garlanda C., Turin L. The expression pattern of TIR8 is conserved among vertebrates. Vet Immunol Immunopathol 2009.
85. Gu Y.F., Fang Y., Jin Y., Dong W.R., Xiang L.X., Shao J.Z. Discovery of the DIGIRR gene from teleost fish: a novel Toll-IL-1 receptor family member serving as a negative regulator of IL-1 signaling. J Immunol 2011, 187:2514-2530.
86. Polentarutti N., Rol G.P., Muzio M., Bosisio D., Camnasio M., Riva F., et al. Unique pattern of expression and inhibition of IL-1 signaling by the IL-1 receptor family member TIR8/SIGIRR. Eur Cytokine Netw 2003, 14:211-218.
87. Kadota C., Ishihara S., Aziz M.M., Rumi M.A., Oshima N., Mishima Y., et al. Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation. Clin Exp Immunol 2010, 162:348-361.
88. Huang X., Hazlett L.D., Du W., Barrett R.P. SIGIRR promotes resistance against Pseudomonas aeruginosa keratitis by down-regulating type-1 immunity and IL-1R1 and TLR4 signaling. J Immunol 2006, 177:548-556.
89. Wald D., Qin J., Zhao Z., Qian Y., Naramura M., Tian L., et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003, 4:920-927.
90. Ragnarsdottir B., Samuelsson M., Gustafsson M.C., Leijonhufvud I., Karpman D., Svanborg C. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J Infect Dis 2007, 196:475-484.
91. Veliz Rodriguez T., Moalli F., Polentarutti N., Paroni M., Bonavita E., Anselmo A., et al. Role of Toll interleukin-1 receptor (IL-1R) 8, a negative regulator of IL-1R/Toll-like receptor signaling, in resistance to acute Pseudomonas aeruginosa lung infection. Infect Immun 2012, 80:100-109.
92. Gopal R., Birdsell D., Monroy F.P. Regulation of toll-like receptors in intestinal epithelial cells by stress and Toxoplasma gondii infection. Parasite Immunol 2008, 30:563-576.
93. Nanthakumar N., Meng D., Goldstein A.M., Zhu W., Lu L., Uauy R., et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PLoS ONE 2011, 6:e61777.
94. Bulek K., Swaidani S., Qin J., Lu Y., Gulen M.F., Herjan T., et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol 2009, 182:2601-2609.
95. Jiang X., McClellan S.A., Barrett R.P., Zhang Y., Hazlett L.D. Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea. J Immunol 2012, 189:269-278.
96. Villena J., Suzuki R., Fujie H., Chiba E., Takahashi T., Tomosada Y., et al. Immunobiotic Lactobacillus jensenii modulates the Toll-like receptor 4-induced inflammatory response via negative regulation in porcine antigen-presenting cells. Clin Vaccine Immunol 2012, 19:1038-1053.
97. Davies J.M., MacSharry J., Shanahan F. Differential regulation of Toll-like receptor signalling in spleen and Peyer's patch dendritic cells. Immunology 2010, 131:438-448.
98. Garlanda C., Riva F., Polentarutti N., Buracchi C., Sironi M., De Bortoli M., et al. Intestinal inflammation in mice deficient in Tir8 an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004, 101:3522-3526.
99. Qin J., Qian Y., Yao J., Grace C., Li X. SIGIRR inhibits interleukin-1 receptor- and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 2005, 280:25233-25241.
100. Lech M., Kulkarni O.P., Pfeiffer S., Savarese E., Krug A., Garlanda C., et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008, 205:1879-1888.
101. Gong J., Wei T., Stark R.W., Jamitzky F., Heckl W.M., Anders H.J., et al. Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: a computational approach. J Struct Biol 2010, 169:323-330.
102. Gulen M.F., Kang Z., Bulek K., Youzhong W., Kim T.W., Chen Y., et al. The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation. Immunity 2010, 32:54-66.
103. Xiao H., Yin W., Khan M.A., Gulen M.F., Zhou H., Sham H.P., et al. Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology 2010, 139:574-585.
104. Xiao H., Gulen M.F., Qin J., Yao J., Bulek K., Kish D., et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 2007, 26:461-475.
105. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
106. Karin M., Lawrence T., Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-835.
107. Garlanda C., Di Liberto D., Vecchi A., La Manna M.P., Buracchi C., Caccamo N., et al. Damping excessive inflammation and tissue damage in Mycobacterium tuberculosis infection by Toll IL-1 receptor 8/single Ig IL-1-related receptor, a negative regulator of IL-1/TLR signaling. J Immunol 2007, 179:3119-3125.
108. Bozza S., Zelante T., Moretti S., Bonifazi P., DeLuca A., D'Angelo C., et al. Lack of Toll IL-1R8 exacerbates Th17 cell responses in fungal infection. J Immunol 2008, 180:4022-4031.
109. Horne D.J., Randhawa A.K., Chau T.T., Bang N.D., Yen N.T., Farrar J.J., et al. Common polymorphisms in the PKP3-SIGIRR-TMEM16J gene region are associated with susceptibility to tuberculosis. J Infect Dis 2012, 205:586-594.
110. Sham H.P., Yu E.Y., Gulen M.F., Bhinder G., Stahl M., Chan J.M., et al. SIGIRR, a negative regulator of TLR/IL-1R signalling promotes microbiota dependent resistance to colonization by enteric bacterial pathogens. PLoS Pathog 2013, 9:e1003539.
111. Leemans J.C., Butter L.M., Teske G.J., Stroo I., Pulskens W.P., Florquin S. The toll interleukin-1 receptor (IL-1R) 8/single Ig domain IL-1R-related molecule modulates the renal response to bacterial infection. Infect Immun 2012, 80:3812-3820.
112. Chen X., Zhao Y., Wu X., Qian G. Enhanced expression of single immunoglobulin IL-1 receptor-related molecule ameliorates LPS-induced acute lung injury in mice. Shock 2011, 35:198-204.
113. Russell S.E., Stefanska A.M., Kubica M., Horan R.M., Mantovani A., Garlanda C., et al. Toll IL-1R8/single Ig IL-1-related receptor regulates psoriasiform inflammation through direct inhibition of innate IL-17A expression by gammadelta T cells. J Immunol 2013, 191:3337-3346.
114. Lech M., Skuginna V., Kulkarni O.P., Gong J., Wei T., Stark R.W., et al. Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J Pathol 2010, 220:596-607.
115. Drexler S.K., Kong P., Inglis J., Williams R.O., Garlanda C., Mantovani A., et al. SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis. Arthritis Rheum 2010, 62:2249-2261.
116. Batliwalla F.M., Li W., Ritchlin C.T., Xiao X., Brenner M., Laragione T., et al. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 2005, 11:21-29.
117. Zhu Y.Y., Su Y., Li Z.G., Zhang Y. The largely normal response to Toll-like receptor 7 and 9 stimulation and the enhanced expression of SIGIRR by B cells in systemic lupus erythematosus. PLoS ONE 2012, 7:e44131.
118. Barry J., Loh Z., Collison A., Mazzone S., Lalwani A., Zhang V., et al. Absence of Toll-IL-1 receptor 8/single immunoglobulin IL-1 receptor-related molecule reduces house dust mite-induced allergic airway inflammation in mice. Am J Respir Cell Mol Biol 2013, 49:481-490.
119. Lech M., Avila-Ferrufino A., Allam R., Segerer S., Khandoga A., Krombach F., et al. Resident dendritic cells prevent postischemic acute renal failure by help of single Ig IL-1 receptor-related protein. J Immunol 2009, 183:4109-4118.
120. Noris M., Cassis P., Azzollini N., Cavinato R., Cugini D., Casiraghi F., et al. The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts. J Immunol 2009, 183:4249-4260.
121. Watson M.B., Costello D.A., Carney D.G., McQuillan K., Lynch M.A. SIGIRR modulates the inflammatory response in the brain. Brain Behav Immun 2010, 24:985-995.
122. Costello D.A., Watson M.B., Cowley T.R., Murphy N., Murphy Royal C., Garlanda C., et al. Interleukin-1alpha and HMGB1 mediate hippocampal dysfunction in SIGIRR-deficient mice. J Neurosci 2011, 31:3871-3879.
123. Costelloe C., Watson M., Murphy A., McQuillan K., Loscher C., Armstrong M.E., et al. IL-1F5 mediates anti-inflammatory activity in the brain through induction of IL-4 following interaction with SIGIRR/TIR8. J Neurochem 2008, 105:1960-1969.
124. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
125. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
126. Garlanda C., Riva F., Veliz T., Polentarutti N., Pasqualini F., Radaelli E., et al. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res 2007, 67:6017-6021.
127. Bertilaccio M.T., Simonetti G., Dagklis A., Rocchi M., Rodriguez T.V., Apollonio B., et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood 2011, 118:660-669.
128. Puente X.S., Pinyol M., Quesada V., Conde L., Ordonez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
129. Muzio M., Scielzo C., Bertilaccio M.T., Frenquelli M., Ghia P., Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009, 144:507-516.
130. Arvaniti E., Ntoufa S., Papakonstantinou N., Touloumenidou T., Laoutaris N., Anagnostopoulos A., et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica 2011, 96:1644-1652.